Literature DB >> 33557518

Allosteric Inhibition of the Epidermal Growth Factor Receptor.

Julie K L Sinclair1, Wesley E Robertson2, Deepto Mozumdar1,3, Kim Quach1, Alanna Schepartz3,4.   

Abstract

We previously reported a family of hydrocarbon-stapled peptides designed to interact with the epidermal growth factor receptor (EGFR) juxtamembrane (JM) segment, blocking its ability to form a coiled coil dimer that is essential for receptor activation. These hydrocarbon-stapled peptides, most notably E1S, decreased the proliferation of cell lines that express wild-type EGFR (H2030 and A431) as well as those expressing the oncogenic mutants EGFR L858R (H3255) and L858R/T790M (H1975). Although our previous investigations provided evidence that E1S interacted with EGFR directly, the location and details of these interactions were not established. Here we apply biochemical and cross-linking mass spectrometry tools to better define the interactions between E1S and EGFR. Taken with previously reported structure-activity relationships, our results support a model in which E1S interacts simultaneously with both the JM and the C-lobe of the activator kinase, effectively displacing the JM of the receiver kinase. Our results also reveal potential interactions between E1S and the N-terminal region of the C-terminal tail. We propose a model in which E1S inhibits EGFR by both mimicking and inhibiting JM coiled coil formation. This model could be used to design novel, allosteric (and perhaps nonpeptidic) EGFR inhibitors.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33557518      PMCID: PMC8815332          DOI: 10.1021/acs.biochem.0c00978

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  73 in total

1.  Investigation of Specific Binding Proteins to Photoaffinity Linkers for Efficient Deconvolution of Target Protein.

Authors:  Jongmin Park; Minseob Koh; Ja Young Koo; Sanghee Lee; Seung Bum Park
Journal:  ACS Chem Biol       Date:  2015-11-03       Impact factor: 5.100

2.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

Review 3.  Lung cancer.

Authors:  Roy S Herbst; John V Heymach; Scott M Lippman
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

Review 4.  Photocrosslinkers illuminate interactions in living cells.

Authors:  Yoshihito Tanaka; Michelle R Bond; Jennifer J Kohler
Journal:  Mol Biosyst       Date:  2008-04-23

Review 5.  Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Klaus F Rabe
Journal:  N Engl J Med       Date:  2017-08-31       Impact factor: 91.245

6.  Rociletinib in EGFR-mutated non-small-cell lung cancer.

Authors:  Lecia V Sequist; Jean-Charles Soria; Jonathan W Goldman; Heather A Wakelee; Shirish M Gadgeel; Andrea Varga; Vassiliki Papadimitrakopoulou; Benjamin J Solomon; Geoffrey R Oxnard; Rafal Dziadziuszko; Dara L Aisner; Robert C Doebele; Cathy Galasso; Edward B Garon; Rebecca S Heist; Jennifer Logan; Joel W Neal; Melody A Mendenhall; Suzanne Nichols; Zofia Piotrowska; Antoinette J Wozniak; Mitch Raponi; Chris A Karlovich; Sarah Jaw-Tsai; Jeffrey Isaacson; Darrin Despain; Shannon L Matheny; Lindsey Rolfe; Andrew R Allen; D Ross Camidge
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

7.  Surveying protein structure and function using bis-arsenical small molecules.

Authors:  Rebecca A Scheck; Alanna Schepartz
Journal:  Acc Chem Res       Date:  2011-07-18       Impact factor: 22.384

Review 8.  Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.

Authors:  X D Yang; X C Jia; J R Corvalan; P Wang; C G Davis
Journal:  Crit Rev Oncol Hematol       Date:  2001-04       Impact factor: 6.312

9.  ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

Authors:  Alan E Wakeling; Simon P Guy; Jim R Woodburn; Susan E Ashton; Brenda J Curry; Andrew J Barker; Keith H Gibson
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

10.  Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations.

Authors:  Jaebong Jang; Ciric To; Dries J H De Clercq; Eunyoung Park; Charles M Ponthier; Bo Hee Shin; Mierzhati Mushajiang; Radosław P Nowak; Eric S Fischer; Michael J Eck; Pasi A Jänne; Nathanael S Gray
Journal:  Angew Chem Int Ed Engl       Date:  2020-07-09       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.